tbuckley/cabot-search huggingface dataset:
Image Gallery: Flagellate dermatitis
Authors: G.U. Sawatkar, K.K. Sahu, G. Prakash, S. Dogra
Journal: British Journal of Dermatology (2016)

Funding sources: none. Conflicts of interest: none declared. Dear Editor, A 62‐year‐old woman was being treated with doxorubicin, bleomycin, vincristine and dacarbazine for Hodgkin lymphoma. Three days after chemotherapy, she complained of generalized pruritus. On examination, multiple erythematous‐to‐violaceous plaques were noted over the back and upper arms, simulating whip marks. Flagellate dermatitis is characterized by parallel linear or curvilinear arranged plaques following the administration of drugs such as bleomycin, docetaxel and bendamustine. Lower levels of bleomycin hydrolase in the skin and lungs lead to inadequate degradation of bleomycin at these sites. Occurrence of bleomycin‐induced skin rash warrants dose reduction and even omission in severe cases. Bleomycin is a common constituent in the armamentarium for haematological malignancy, hence it is not uncommon to encounter such adverse effects.
TCTAP A-124 Comparable Effectiveness Between Aspirin, Clopidogrel and Dual Antiplatelet Therapy in Very Elderly Patients with Medically Managed Acute Myocardial Infarction
Authors: Lin Ting-Tse, Min-Tsun Liao, Choa-Lun Lai
Journal: Journal of the American College of Cardiology (2016)
A Clinical Approach to the Diagnosis of Traumatic Encephalopathy Syndrome
Authors: Nicole Reams, James T. Eckner, Andrea A. Almeida, Andrea L. Aagesen, Bruno Giordani, Hank Paulson, Matthew T. Lorincz, Jeffrey S. Kutcher
Journal: JAMA Neurology (2016)

Chronic traumatic encephalopathy (CTE) refers to pathologic changes that have been found in some individuals with a history of repetitive traumatic impact to the head (hereinafter referred to as head trauma). These changes cannot be assessed during the clinical evaluation of a living patient.
Lymphatic System in Cardiovascular Medicine
Authors: Aleksanteri Aspelund, Marius R. Robciuc, Sinem Karaman, Taija Makinen, Kari Alitalo
Journal: Circulation Research (2016)

The mammalian circulatory system comprises both the cardiovascular system and the lymphatic system. In contrast to the blood vascular circulation, the lymphatic system forms a unidirectional transit pathway from the extracellular space to the venous system. It actively regulates tissue fluid homeostasis, absorption of gastrointestinal lipids, and trafficking of antigen-presenting cells and lymphocytes to lymphoid organs and on to the systemic circulation. The cardinal manifestation of lymphatic malfunction is lymphedema. Recent research has implicated the lymphatic system in the pathogenesis of cardiovascular diseases including obesity and metabolic disease, dyslipidemia, inflammation, atherosclerosis, hypertension, and myocardial infarction. Here, we review the most recent advances in the field of lymphatic vascular biology, with a focus on cardiovascular disease.
Pulmonary haemodynamics during recovery from maximum incremental cycling exercise
Authors: Rudolf K.F. Oliveira, Aaron B. Waxman, Manyoo Agarwal, Roza Badr Eslam, David M. Systrom
Journal: European Respiratory Journal (2016)

Assessment of cardiac function during exercise can be technically demanding, making the recovery period a potentially attractive diagnostic window. However, the validity of this approach for exercise pulmonary haemodynamics has not been validated. The present study, therefore, evaluated directly measured pulmonary haemodynamics during 2-min recovery after maximum invasive cardiopulmonary exercise testing in patients evaluated for unexplained exertional intolerance. Based on peak exercise criteria, patients with exercise pulmonary hypertension (ePH; n=36), exercise pulmonary venous hypertension (ePVH; n=28) and age-matched controls (n=31) were analysed. By 2-min recovery, 83% (n=30) of ePH patients had a mean pulmonary artery pressure (mPAP) &lt;30 mmHg and 96% (n=27) of ePVH patients had a pulmonary arterial wedge pressure (PAWP) &lt;20 mmHg. Sensitivity of pulmonary hypertension-related haemodynamic measurements during recovery for ePH and ePVH diagnosis was ≤25%. In ePVH, pulmonary vascular compliance (PVC) returned to its resting value by 1-min recovery, while in ePH, elevated pulmonary vascular resistance (PVR) and decreased PVC persisted throughout recovery. In conclusion, we observed that mPAP and PAWP decay quickly during recovery in ePH and ePVH, compromising the sensitivity of recovery haemodynamic measurements in diagnosing pulmonary hypertension. ePH and ePVH had different PVR and PVC recovery patterns, suggesting differences in the underlying pulmonary hypertension pathophysiology.
Function of the interleukin-2 (IL-2) receptor gamma-chain in biologic responses of X-linked severe combined immunodeficient B cells to IL-2, IL-4, IL-13, and IL-15
Authors: DJ Matthews, PA Clark, J Herbert, G Morgan, RJ Armitage, C Kinnon, A Minty, KH Grabstein, D Caput, P Ferrara
Journal: Blood (1995)
Results of a phase I/II trial of recombinant human granulocyte- macrophage colony-stimulating factor in very low birthweight neonates: significant induction of circulatory neutrophils, monocytes, platelets, and bone marrow neutrophils
Authors: MS Cairo, R Christensen, LS Sender, R Ellis, J Rosenthal, C van de Ven, C Worcester, JM Agosti
Journal: Blood (1995)
TCTAP C-222 Incidence of Floating Stent Fracture 141 Months After Luminexx Nitinol Stent Implantation in the Superficial Femoral Artery
Authors: Takuya Tsujimura, Osamu Iida, Shin Okamoto, Takayuki Ishihara, Kiyonori Nanto, Tatsuya Shiraki, Shota Okuno, Koji Yanaka, Masaaki Uematsu
Journal: Journal of the American College of Cardiology (2016)
An In Situ Gelling Drug Delivery System for Improved Recovery after Spinal Cord Injury
Authors: Dongfei Liu, Tao Jiang, Weihua Cai, Jian Chen, Hongbo Zhang, Sami Hietala, Hélder A. Santos, Guoyong Yin, Jin Fan
Journal: Advanced Healthcare Materials (2016)

Therapeutic strategies for the spinal cord injury (SCI) are limited by the current available drug delivery techniques. Here, an in situ gelling drug delivery system (DDS), composed of a Poloxamer‐407, a 188 mixture‐based thermoresponsive hydrogel matrix and, an incorporated therapeutic compound (monosialoganglioside, GM1), is developed for SCI therapy. A low‐thoracic hemisection in rats is used as SCI model to evaluate therapeutic efficiency. The GM1‐incorporating Poloxamer‐407 and 188 polymer solution is converted to a hydrogel (GM1‐hydrogel) upon instillation to the injured spinal cord, due to the increased temperature. At body temperature, the thermoresponsive hydrogel prolongs the release of GM1 for about 1 month, due to the superposition of dissolution and swelling (anomalous transport) of the hydrogel matrix. The sustained release of the GM1‐hydrogel enables the prolonged residence time of GM1 at the injured spinal cord, decreases the frequency of administration and, consequently, may improve patient compliance. After SCI, the administration of GM1‐hydrogel to the lesion site inhibits the apoptotic cell death and glial scar formation, enhances the neuron regeneration, provides neuroprotection to the injured spinal cord, and improves the locomotor recovery. Overall, this study opens future perspectives for the treatment of SCI with a prolonged drug release DDS.
Autologous Stem Cell Transplantation for Follicular Lymphoma in the Era of Rutiximab: Cleveland Clinic Experience
Authors: Deepa Jagadeesh, Lisa Rybicki, Donna M Abounader, Brian T. Hill, Robert M Dean, Hien K. Duong, Ronald M. Sobecks, Betty K. Hamilton, Aaron Gerds, Christina Ferraro, Gina Green, Kelly Cherni, Brad Pohlman, Matt E. Kalaycio, Brian J. Bolwell, Navneet S. Majhail
Journal: Blood (2014)
Systems-Level Resources for Pulmonary Nodule Evaluation in the United States: A National Survey
Authors: James Simmons, Michael K. Gould, Jonathan Iaccarino, Christopher G. Slatore, Renda Soylemez Wiener
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Each year, more than 1.5 million Americans are found to have a pulmonary nodule (1).As lung cancer screening becomes prevalent, still more nodules will be identified.Whether detected incidentally or through screening, guidelines recommend evaluating pulmonary nodules in a timely fashion to identify the subset that are malignant.Yet patients with pulmonary nodules often do not receive appropriate evaluation, seemingly "falling through the cracks" (2, 3).Systems-level structures and processes of care have been proposed to facilitate appropriate, efficient nodule evaluation (4-8), and indeed, clinicians have indicated that such system-level resources are essential to avoid loss to follow-up (9).However, the degree to which these structures and processes of care have been implemented nationally is unclear, and the American Thoracic Society (ATS) has called for more research in this area (10).We conducted a survey of ATS clinicians to characterize the availability of system-level resources to facilitate pulmonary nodule evaluation in the United States. MethodsWe surveyed clinician members of the ATS Respiratory Cell and Molecular Biology and Clinical Problems Assemblies (the parent assemblies of the Section of Thoracic Oncology at the time of survey administration).Eligible clinicians included physicians or midlevel providers who regularly saw patients in an outpatient clinic.ATS sent three e-mails in March and April 2014, inviting clinicians to participate in an anonymous online survey, with a $50 incentive for completion.The 32-item survey asked about demographics, practice setting, and practices regarding lung cancer screening and nodule evaluation.The Boston University Institutional Review Board approved this study.Although this was an international survey, we restricted analysis to responses from U.S. clinicians, given differences in resource availability and practice patterns across countries.Proportions were compared using chi-squared tests, and medians with the Kruskal-Wallis test, with two-sided a , 0.05 as the threshold for statistical significance.All data were analyzed using Stata 10.1 (College Station, TX).
TCTAP A-154 Effects of Transcatheter Paravalvular Leak Closure on Hemolytic Anemia
Authors: Grzegorz Smolka, Andrzej Ochala, Piotr Pysz, Michal Kozlowski, Wojciech Zasada, Zofia Parma, Michal Tendera, Wojciech Wojakowski
Journal: Journal of the American College of Cardiology (2016)
Response to Open Peer Commentaries on “Bioethicists Can and Should Contribute to Addressing Racism”
Authors: Yolonda Wilson, Marion Danis, Amina White
Journal: The American Journal of Bioethics (2016)

We appreciate the ten thoughtful commentaries on our target article “Bioethicists Can and Should Contribute to Addressing Racism” (Danis, Wilson, and White 2016). Two of these commentaries challeng...
TCT-472 Clinical outcomes of “Full Metal Jacket” procedure after Percutaneous Coronary Intervention for Chronic Total Occlusion
Authors: Cheol Hyun Lee, Yu Na Kim, Hee-Soon Park, Pil Hyung Lee, Mineok Chang, Jae-Hyung Roh, Sung-Han Yoon, Jung-Min Ahn, Soo-Jin Kang, Duk-Woo Park, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2015)
Soundings: The old and the new
Authors: Colin Douglas
Journal: BMJ (2001)

In a crowded lift in a fairly important building in London's political village there was a momentary drama. The doors closed, the lift lurched upwards, then dropped a few inches. Assorted apparatchiks and policy wonks glanced at each other nervously. A squat, square middle-aged man looked upwards, shook his head and murmured, “Bloody winding engineers.” I laughed, but no one else did.

He was vaguely familiar—an MP and former miner—and definitely old Labour. I remembered where I'd met him first. We were both at work in an unwinnable constituency in what turned out to be an unwinnable election, that of 1979. The candidate was a novice—pale and intense, committed and convincing—and a lot of people turned out to help.

I had never been as close to real politics before and found it all very interesting. Campaign headquarters was an abandoned butcher's shop in the middle of a shabby housing estate. Everyone else seemed to know what they were doing. I watched a bit, asked sometimes, and learned the basics. In the run-up we stuffed envelopes and knocked on doors. Late on the day itself, as the owner of a respectable, safe and fully insured car, I was sent out with the former miner, who was then a trade union official, to round up the last of the vote.

He was forceful and persuasive. Memorably, he marched into a busy, scruffy pub, called for silence, then asked, “Any o' ye here no' voted . . .? Right. Intae the car. We've got 10 minutes.” I drove three bewildered youths and their captor to the polling station, suddenly convinced that our candidate would take the seat, by a majority of just one or two votes.

He didn't. He knew he wouldn't. After the polls closed, and amid the meat hooks and white tiles of his campaign HQ, he led us—students, pensioners, miners, friends—as we sang: “The people's flag is deepest red . . .” Tears flowed and life-long allegiances were reaffirmed.

An election or two later the trade union official was in parliament, representing a nearby constituency. He served the people of its former mining towns and villages faithfully and stood down just a few weeks ago, one of the last of an old tradition.

And the pale, young candidate? He tried again in a more promising seat, entered parliament, did well in opposition, and is now, I believe, quite highly regarded for his work as chancellor of the Exchequer.
A prospective biomarker study in afatinib-treated patients with EGFR-mutation positive non-small cell lung cancer
Authors: Eiji Iwama, Kazuko Sakai, Koichi Azuma, Kaname Nozaki, Daijiro Harada, Katsuyuki Hotta, Fumiyoshi Ohyanagi, Yoichi Nakanishi, Kazuto Nishio, Isamu Okamoto
Journal: Annals of Oncology (2015)
A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children’s Oncology Group
Authors: L Eidenschink Brodersen, T A Alonzo, A J Menssen, R B Gerbing, L Pardo, A P Voigt, S B Kahwash, B Hirsch, S Raimondi, A S Gamis, S Meshinchi, M R Loken
Journal: Leukemia (2016)
Film: EXIT—le droit de mourir
Authors: Raghav Chawla
Journal: BMJ (2005)

Switzerland is known not only for its snow covered mountains and for its chocolate but also for its liberal legislation with regard to assisted suicide. If no selfish motive is involved, suicide assistance—for example, by providing the necessary drugs—is legal even by non-doctors. Active euthanasia, however, remains illegal under all circumstances.​circumstances.




Figure 1




Suicide assistance is largely offered by three organisations in Switzerland: EXIT for German speaking Switzerland; EXIT for French speaking Switzerland, also known as EXIT ADMD; and Dignitas. Unlike Dignitas, which also caters for non-residents and has prompted much debate about suicide tourism, both EXIT associations offer their services to Swiss residents only.

Filmmaker Fernand Melgar was first confronted with an incidence of assisted suicide while watching a news report a few years ago. “The report did somewhat shake me up, although I never questioned the choice of the suicide candidate,” he recalls. “It was more the suicide assistant's perspective that bewildered me—what would motivate someone to take on such a responsibility?”

Melgar contacted EXIT ADMD with the idea of making a documentary film. In view of the delicacy of the subject, the society's president, Dr Jerome Sobel, initially hesitated to agree to the project. “Then again, we had nothing to hide,” he says. Melgar was eventually given the opportunity film virtually all of the society's activities over a year.

The result of this experiment is astounding. EXIT, as the film has been named, is basically a compilation of typical scenes from the society's daily life. Perhaps in an attempt to let the viewer make their own decisions, Melgar does not impose his own interpretation—Melgar merely takes the role of the passive observer. There is no narrative to guide you nor is there a journalist interviewing anyone and summarising things for you. Instead the film builds on the intimate conversations between its characters, including suicide candidates, other members of EXIT, relatives, friends, accompanying volunteer workers, secretaries, and others.

Little by little, the viewer learns about the motivations of candidates for suicide, their ups and downs, and about their feelings for their loved ones. We learn how difficult it is to be an accompanying volunteer worker. “This is not something you can do as regularly as clockwork. It's an exceptional act every single time. I'm exhausted after every assisted suicide,” Dr Sobel says.

Ultimately, the film shows how peaceful the process of an assisted suicide can be. They simply drink a glass of “magic potion” and fade in the company of their loved ones.
Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype
Authors: D Ben-Yehuda, S Krichevsky, O Caspi, D Rund, A Polliack, D Abeliovich, O Zelig, V Yahalom, O Paltiel, R Or, T Peretz, S Ben-Neriah, O Yehuda, EA Rachmilewitz
Journal: Blood (1996)
Policy is mechanism by which decisions might be reached
Authors: D De Takats
Journal: BMJ (1996)

Fundholding practice's draft policy on ethical use of resourcesPolicy is inconsistent EDrrOR,-The Asbury draft policy on ethical use of resources, a document developed by a fundholding practice to clarify the ethical basis of decisions concerning rationing, contains many inconsistencies.'Two of these, in particular, must be challenged-namely, those to do with age and patients' responsibility for their conditions.With regard to age, the authors seem to want to have it both ways.They first reject the view that treatment should be denied on the basis of age but later write, "the patients' ages may be considered and found relevant."They take this view not because of any medical criteria but because of the "fair innings" argument.In addition to being inconsistent in their views, the authors seem to ignore both the many persuasive arguments against the fair innings argument2 and the difficulty of defining fairness (Rawls, for instance, tried to do so and failed3).They also imply that quality adjusted life years should not be considered in the treatment of patients who are terminally ill but seem to accept that they should be considered with regard to age.Why?It is not only about age that the authors are in two minds: they take the same stance with patients' responsibility for their conditions.They first reject the idea that treatment should be denied on the grounds that the patient has brought the condition on himselfor herself, but then they write, "the issue of a patient's responsibility for having induced the problem might be considered relevant."It is surprising that the authors have not realised the inconsistencies in their views here.It is even more important that they have not taken account of the fact that if we start allocating health care on the basis of personal responsibility there will be few people eligible for treatment.
Abstract A31: Cyclic NGR peptide functionalized PEG-PLGA nanoparticles as dual-targeting carrier for site specific antitumor drug delivery
Authors: Dr. Madhu Gupta, Dr. Vikas Sharma, Prof. G.P. Agrawal, Prof. S.P. Vyas
Journal: Cancer Research (2015)

Abstract CD13 receptors are abundantly overexpressed in tumor cells as well as in neovasculature. The polymeric nanoparticles (NPs) as the nanomodules for anticancer drug carriers are well known. Nowadays, targeted delivery options are becoming a fascinating approach, so CD13 receptors was selected as a targeted site and NPs as a delivery system. By combining all the issue, a cyclic NGR (cNGR) peptide as a ligand was coupled on the terminal end of polyethylene glycol-b-poly(lactic-co-glycolic acid) (PEG-b-PLGA) and prepared the dual targeted polymeric NPs (cNGR-PEG-PTX-NPs) in order to enhance the intracellular delivery of anticancer drug to the tumor cells and tumor endothelial cells via ligand-receptor interaction. In-vitro cytotoxicity studies confirmed that the presence of cNGR enhanced the cytotoxic efficiency by 2.8 folds in human umbilical vein endothelial (HUVEC) cells, while cytotoxicity was improved by 2.6 folds in human fibrosarcoma (HT-1080) cells as compared to non-specific stealth NPs. Compared with other tested NPs, cNGR-PEG-PTX-NPs revealed more cytotoxicity by inducing more apoptosis, higher cell uptake and more G2/M phase arrest. The tumor volume inhibition rate was 59.7% in case of cNGR-PEG-PTX-NPs that was comparatively more with other formulations, indicating that cNGR-PEG-PTX-NPs could more effectively inhibit tumor growth. As a consequence, the cNGR-PEG-PTX-NPs play a key role in enhancing tumor therapeutic efficiency for treatment of CD13 receptor specific solid tumor. Citation Format: Dr. Madhu Gupta, Sr., Dr. Vikas Sharma, Prof. G.P. Agrawal, Prof. S.P. Vyas. Cyclic NGR peptide functionalized PEG-PLGA nanoparticles as dual-targeting carrier for site specific antitumor drug delivery. [abstract]. In: Proceedings of the AACR Special Conference: Advances in Brain Cancer Research; May 27-30, 2015; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2015;75(23 Suppl):Abstract nr A31.
Specialty-Based Global Payment
Authors: Zirui Song, Carrie H. Colla
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal